Is excitation-contraction coupling impaired in myasthenia gravis?

Clin Neurophysiol. 2007 May;118(5):1144-8. doi: 10.1016/j.clinph.2007.01.001. Epub 2007 Feb 16.

Abstract

Objective: To investigate whether excitation-contraction (E-C) coupling of muscle is impaired in patients with myasthenia gravis (MG).

Methods: In 51 patients with generalized MG and 35 normal subjects, compound muscle action potentials (CMAPs) of the abductor pollicis brevis, and movement-related potentials using an accelerometer placed at the thumb tip were simultaneously recorded after median nerve stimulation at the wrist. The E-C coupling time (ECCT) was estimated by a latency difference between CMAP and movement-related potential. Antibodies against acetylcholine receptor (AChR), ryanodine receptor (RyR), and muscle specific receptor tyrosine kinase (MuSK) were measured by immunoassays.

Results: The mean ECCT was significantly longer in patients with MG (mean+/-SEM; 2.79+/-0.1 ms; p=0.002) than in normal controls (2.52+/-0.1 ms). Among MG patients, the mean ECCT was longer for patients with thymoma than for those without it (P=0.04), and was shorter for patients treated with FK506 (an immunosuppressant and also an enhancer of RyR related Ca(2+) release) than for those not receiving this treatment (p=0.04). ECCT had no significant correlation with anti-AChR, anti-RyR, or anti-MuSK antibodies.

Conclusions: In MG, E-C coupling appears to be impaired, particularly in patients with thymoma, and FK506 possibly facilitates E-C coupling.

Significance: The functional implication of impaired E-C coupling is not established, but it may contribute to muscle weakness in patients with MG.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / physiology
  • Adult
  • Aged
  • Electric Stimulation
  • Electromyography
  • Female
  • Humans
  • Immunohistochemistry
  • Immunosuppressive Agents / pharmacology
  • Intercostal Muscles / physiopathology
  • Male
  • Middle Aged
  • Muscle Contraction / physiology
  • Muscle, Skeletal / physiopathology*
  • Myasthenia Gravis / complications
  • Myasthenia Gravis / physiopathology*
  • Protein-Tyrosine Kinases / metabolism
  • Receptors, Cholinergic / metabolism
  • Ryanodine Receptor Calcium Release Channel / metabolism
  • Tacrolimus / pharmacology
  • Thymoma / complications
  • Thymoma / physiopathology
  • Thymus Neoplasms / complications
  • Thymus Neoplasms / physiopathology

Substances

  • Immunosuppressive Agents
  • Receptors, Cholinergic
  • Ryanodine Receptor Calcium Release Channel
  • Protein-Tyrosine Kinases
  • Tacrolimus